Walter Hsu

Dr. Walter Hsu


Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Life Sciences
Verified
Journal Article
Closed access
TCTyler Crowe
Tyler Crowe
MGM. Heather West Greenlee
M. Heather West Greenlee
AKAnumantha Gounder Kanthasamy
Anumantha Gounder Kanthasamy
WHWalter Hsu
Walter Hsu

1 October 2017 in Biomedical Journal
Verified
Journal Article
Open access
SHSamantha Hurrle
Samantha Hurrle
WHWalter Hsu
Walter Hsu
Insulin resistance is a prevalent syndrome in developed as well as developing countries. It is the predisposing factor for type 2 diabetes mellitus, the most common end stage development of metabolic syndrome in the United States. Previously, studies investigating type 2 diabetes have focused on beta cell dysfunction in the pancreas and insulin resistance, and developing ways to correct these dysfunctions. However, in recent years, there has been a profound interest in the role that oxidative stress in the peripheral tissues plays to induce insulin resistance. The objective of this review is to focus on the mechanism of oxidative species generation and its direct correlation to insulin resistance, to discuss the role of obesity in the pathophysiology of this phenomenon, and to explore the potential of antioxidants as treatments for metabolic dysfunction.

12 March 2022 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
TCTyler Crowe
Tyler Crowe
WHWalter Hsu
Walter Hsu
Neurological diseases continue to increase in prevalence worldwide. Combined with the lack of modifiable risk factors or strongly efficacious therapies, these disorders pose a significant and growing burden on healthcare systems and societies. The development of neuroprotective or curative therapies is limited by a variety of factors, but none more than the highly selective blood-brain barrier. Intranasal administration can bypass this barrier completely and allow direct access to brain tissues, enabling a large number of potential new therapies ranging from bioactive peptides to stem cells. Current research indicates that merely administering simple solutions is inefficient and may limit therapeutic success. While many therapies can be delivered to some degree without carrier molecules or significant modification, a growing body of research has indicated several methods of improving the safety and efficacy of this administration route, such as nasal permeability enhancers, gelling agents, or nanocarrier formulations. This review shall discuss promising delivery systems and their role in expanding the clinical efficacy of this novel administration route. Optimization of intranasal administration will be crucial as novel therapies continue to be studied in clinical trials and approved to meet the growing demand for the treatment of patients with neurological diseases.

25 April 2018 in British Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
YHY. Hu
Y. Hu
CCC. Converse
C. Converse
MLM. C. Lyons
M. C. Lyons
WHWalter Hsu
Walter Hsu

17 March 2021 in Journal of Veterinary Pharmacology and Therapeutics
Verified
Journal Article
Open access
PDF file
XZXueying Zhou
Xueying Zhou
AHAlexandra E. Hohman
Alexandra E. Hohman
WHWalter Hsu
Walter Hsu
The isoxazolines are a novel class of ectoparasiticides with potent inhibitory activity on glutamate‐ and gamma‐aminobutyric acid‐gated chloride channel located in nervous system of invertebrates. In recent years, studies have been performed to evaluate the efficacy and safety of isoxazolines against various types of ectoparasites, including fleas, ticks, and mites. As more single and combined isoxazoline products have been approved by the United States Food and Drug Administration and European Medicines Agency, a more comprehensive understanding of isoxazolines becomes essential for veterinary clinical practitioners. This article provides a complete review of isoxazolines with respect to pharmacodynamics, pharmacokinetics, ectoparasiticidal efficacy, and safety, which will provide veterinarians information to allow them to make the best choice of ectoparasiticide for their clients’ specific needs.

26 June 2023 in Pathogens
Verified
Journal Article
Open access
PDF file
SASekendar Ali
Sekendar Ali
ELEon-Bee Lee
Eon-Bee Lee
WHWalter Hsu
Walter Hsu
Kyoungho SukKyoungho Suk
Kyoungho Suk
SSSyed Al Jawad Sayem
Syed Al Jawad Sayem
Seung-Chun ParkSeung-Chun Park
Seung-Chun Park
Probiotics are being used as feed/food supplements as an alternative to antibiotics. It has been demonstrated that probiotics provide several health benefits, including preventing diarrhea, irritable bowel syndrome, and immunomodulation. Alongside probiotic bacteria-fermented foods, the different structural components, such as lipoteichoic acids, teichoic acids, peptidoglycans, and surface-layer proteins, offer several advantages. Probiotics can produce different antimicrobial components, enzymes, peptides, vitamins, and exopolysaccharides. Besides live probiotics, there has been growing interest in consuming inactivated probiotics in farm animals, including pigs. Several reports have shown that live and killed probiotics can boost immunity, modulate intestinal microbiota, improve feed efficiency and growth performance, and decrease the incidence of diarrhea, positioning them as an interesting strategy as a potential feed supplement for pigs. Therefore, effective selection and approach to the use of probiotics might provide essential features of using probiotics as an important functional feed for pigs. This review aimed to systematically investigate the potential effects of lactic acid bacteria in their live and inactivated forms on pigs.